Treatment of H. pylori Infection in Children
For confirmed H. pylori infection in children with persistent dyspeptic symptoms or peptic ulcer disease, use 14-day bismuth quadruple therapy (PPI + bismuth + metronidazole + tetracycline) as first-line treatment, or if bismuth is unavailable, use 14-day concomitant quadruple therapy (PPI + amoxicillin + metronidazole + clarithromycin).
First-Line Treatment Selection
The pediatric-specific ESPGHAN/NASPGHAN guidelines emphasize that treatment should ideally be tailored to antibiotic susceptibility testing to achieve the goal of >90% eradication rates 1. However, when susceptibility testing is unavailable (the usual clinical scenario), you must select empiric therapy based on local resistance patterns.
Recommended First-Line Regimens (14 days):
Bismuth Quadruple Therapy (preferred):
- PPI (standard dose) twice daily
- Bismuth subsalicylate 262-524 mg four times daily
- Metronidazole 250-500 mg three to four times daily (dose adjusted for age/weight)
- Tetracycline 500 mg four times daily (for children ≥8 years)
This regimen is favored because it maintains efficacy even with metronidazole-resistant strains and avoids clarithromycin, where resistance rates are climbing 2, 1.
Concomitant Non-Bismuth Quadruple Therapy (when bismuth unavailable):
- PPI twice daily
- Amoxicillin 50 mg/kg/day (max 1000 mg) twice daily
- Metronidazole 20 mg/kg/day (max 500 mg) twice daily
- Clarithromycin 15 mg/kg/day (max 500 mg) twice daily
This is recommended by all major consensus groups as first-line when bismuth is not accessible 2.
High-Dose Triple Therapy (alternative when susceptibility known):
- PPI twice daily
- Amoxicillin 50 mg/kg/day twice daily
- Metronidazole 20 mg/kg/day twice daily
Use this only when clarithromycin resistance is documented or suspected in your region 1. Recent pediatric data shows amoxicillin-based regimens achieve 84% eradication versus 67.6% for metronidazole-based therapy 3, though this study used triple rather than quadruple therapy.
Critical Treatment Principles
Duration Matters
All first-line therapies must be given for 14 days 4, 1. The Toronto Consensus concluded definitively that 14 days achieves higher success than shorter durations, and the pediatric guidelines align with this recommendation 2, 1.
Avoid These Common Pitfalls:
- Do NOT use clarithromycin-containing regimens without susceptibility testing in areas with >15% clarithromycin resistance 1
- Do NOT use standard-dose triple therapy (PPI + amoxicillin + clarithromycin) as first-line—it is explicitly restricted by all consensus groups due to poor eradication rates 2
- Do NOT use sequential or hybrid therapies—these are considered non-ideal options 2
- Emphasize strict adherence—success depends on >90% medication compliance 4
Post-Treatment Confirmation
Confirm eradication 4-8 weeks after completing therapy using ¹³C urea breath test or stool antigen test 1, 5. Do not use serology for post-treatment assessment as antibodies persist despite successful eradication.
Recurrence Monitoring
Recurrence occurs in approximately 13.7% of successfully treated children, predominantly in those younger than 10 years, with most cases identified between 6-12 months post-eradication 3. Schedule follow-up at 6 and 12 months for younger children to detect reinfection early.
When Susceptibility Testing is Available
If culture or molecular testing reveals clarithromycin susceptibility, you may use PPI + amoxicillin + clarithromycin for 14 days, though this is increasingly rare given rising resistance 1. The pediatric guidelines strongly advocate for broader availability of susceptibility testing to individualize therapy 1.
Rescue Therapy (If First-Line Fails)
If initial treatment fails:
- Levofloxacin triple therapy (PPI + amoxicillin + levofloxacin) for 14 days is recommended by all groups as rescue 2
- Bismuth quadruple therapy if not used first-line 2
- Consider rifabutin-containing regimens as third or fourth-line 2
The key difference from adult guidelines is that pediatric treatment absolutely requires confirmed diagnosis via endoscopy with biopsy-based methods before initiating therapy—test-and-treat strategies are never appropriate in children 1, 5, 6.